Profile data is unavailable for this security.
About the company
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
- Revenue in USD (TTM)2.60m
- Net income in USD-39.87m
- Incorporated2020
- Employees57.00
- LocationSAB Biotherapeutics Inc777 W 41St St, Suite 401MIAMI BEACH 33140United StatesUSA
- Phone+1 (305) 845-2813
- Fax+1 (302) 636-5454
- Websitehttps://www.sab.bio/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yubo International Biotech Ltd | 455.72k | -1.26m | 23.98m | 18.00 | -- | -- | -- | 52.61 | -0.0105 | -0.0105 | 0.0038 | -0.0172 | 0.2488 | 0.4126 | 5.27 | 25,317.78 | -70.32 | -- | -- | -- | 80.24 | -- | -282.61 | -- | 0.1487 | -4,023.75 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Janone Inc | 0.00 | -18.58m | 24.16m | 5.00 | -- | -- | -- | -- | -3.66 | -3.95 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -69.38 | -23.12 | -88.46 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.1264 | -- | -- | -- | -313.15 | -- | -- | -- |
| Sol Gel Technologies Ltd | 1.72m | -22.86m | 25.07m | 36.00 | -- | 0.7679 | -- | 14.58 | -0.8222 | -0.8222 | 0.0619 | 1.17 | 0.0387 | -- | 0.5154 | 47,777.78 | -51.40 | -31.60 | -57.29 | -35.49 | -- | -- | -1,329.13 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 25.34m | 8.00 | -- | 2.18 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| BioVie Inc | 0.00 | -37.18m | 25.43m | 18.00 | -- | 1.34 | -- | -- | -0.9626 | -0.9626 | 0.00 | 0.3104 | 0.00 | -- | -- | 0.00 | -94.32 | -456.35 | -149.75 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.2969 | -- | -- | -- | -92.67 | -- | -- | -- |
| Dare Bioscience Inc | 2.82m | -28.87m | 26.03m | 23.00 | -- | -- | -- | 9.24 | -3.81 | -3.81 | 0.37 | -1.31 | 0.1299 | -- | 1.49 | 122,486.50 | -133.12 | -109.51 | -4,386.38 | -246.26 | 0.0579 | -- | -1,024.93 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Correlate Energy Corp | 7.95m | -13.85m | 26.08m | 19.00 | -- | -- | -- | 3.28 | -0.3747 | -0.3747 | 0.2157 | -0.145 | 2.76 | -- | 26.10 | 418,160.50 | -481.76 | -315.47 | -- | -- | 17.98 | 15.42 | -174.38 | -201.03 | -- | -1.07 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -8.05m | 26.83m | 8.00 | -- | 10.69 | -- | -- | -0.7249 | -0.7249 | 0.00 | 0.1048 | 0.00 | -- | -- | 0.00 | -172.23 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.60m | -39.87m | 27.04m | 57.00 | -- | 0.5119 | -- | 10.39 | -6.26 | -6.26 | 0.396 | 5.72 | 0.0456 | -- | 5.44 | 45,657.37 | -69.91 | -- | -86.60 | -- | -- | -- | -1,531.84 | -- | -- | -- | 0.0762 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -15.53m | 27.25m | 29.00 | -- | -- | -- | -- | -0.3227 | -0.3227 | 0.00 | -0.0811 | 0.00 | -- | -- | 0.00 | -276.90 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 27.31m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 0.00 | -25.65m | 27.61m | 2.00 | -- | -- | -- | -- | -2.06 | -2.06 | 0.00 | -1.54 | 0.00 | -- | -- | -- | -200.56 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 11.32m | -63.03m | 28.12m | 100.00 | -- | 0.270 | -- | 2.48 | -1.66 | -1.66 | 0.2987 | 2.73 | 0.0649 | -- | -- | 113,240.00 | -36.11 | -48.32 | -39.88 | -54.03 | -- | -- | -556.59 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Palatin Technologies, Inc. | 5.90m | -32.20m | 28.40m | 34.00 | -- | 17.99 | -- | 4.81 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| Lisata Therapeutics Inc | 0.00 | -20.05m | 28.49m | 25.00 | -- | 0.6627 | -- | -- | -2.46 | -2.46 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -35.01 | -45.97 | -38.40 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
Data as of Jul 03 2024. Currency figures normalised to SAB Biotherapeutics Inc's reporting currency: US Dollar USD
35.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Mar 2024 | 917.83k | 9.95% |
| BVF Partners LPas of 31 Mar 2024 | 917.83k | 9.95% |
| Marshall Wace LLPas of 31 Mar 2024 | 459.17k | 4.98% |
| Sessa Capital IM LPas of 13 May 2024 | 458.46k | 4.97% |
| Commodore Capital LPas of 31 Mar 2024 | 183.17k | 1.99% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 175.20k | 1.90% |
| Geode Capital Management LLCas of 31 Mar 2024 | 63.47k | 0.69% |
| Millennium Management LLCas of 31 Mar 2024 | 54.05k | 0.59% |
| Pathstone Family Office LLCas of 31 Mar 2024 | 50.65k | 0.55% |
| First Manhattan Co LLCas of 31 Mar 2024 | 24.58k | 0.27% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
